The EDGE

How to manage high-risk acute myeloid leukemia

E H Estey

Leukemia 2012 26: 861-869; advance online publication, November 25, 2011; 10.1038/leu.2011.317

How to manage polycythemia vera

F Passamonti

Leukemia 2012 26: 870-874; advance online publication, December 9, 2011; 10.1038/leu.2011.334

How to manage essential thrombocythemia

G Finazzi

Leukemia 2012 26: 875-882; advance online publication, November 4, 2011; 10.1038/leu.2011.306

Original Articles

MOLECULAR TARGETS FOR THERAPY

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

Y Tabe, L Jin, K Iwabuchi, R-Y Wang, N Ichikawa, T Miida, J Cortes, M Andreeff and M Konopleva

Leukemia 2012 26: 883-892; advance online publication, October 18, 2011; 10.1038/leu.2011.291

ACUTE LEUKEMIAS

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

D A Pollyea, H E Kohrt, L Gallegos, M E Figueroa, O Abdel-Wahab, B Zhang, S Bhattacharya, J Zehnder, M Liedtke, J R Gotlib, S Coutre, C Berube, A Melnick, R Levine, B S Mitchell and B C Medeiros

Leukemia 2012 26: 893-901; advance online publication, October 28, 2011; 10.1038/leu.2011.294

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia

E Ellinghaus, M Stanulla, G Richter, D Ellinghaus, G te Kronnie, G Cario, G Cazzaniga, M Horstmann, R Panzer Grümayer, H Cavé, J Trka, O Cinek, A Teigler-Schlegel, A ElSharawy, R Häsler, A Nebel, B Meissner, T Bartram, F Lescai, C Franceschi, M Giordan, P Nürnberg, B Heinzow, M Zimmermann, S Schreiber, M Schrappe and A Franke

Leukemia 2012 26: 902-909; advance online publication, November 11, 2011; 10.1038/leu.2011.302

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

E McCormack, I Haaland, G Venås, R B Forthun, S Huseby, G Gausdal, S Knappskog, D R Micklem, J B Lorens, Ø Bruserud and B T Gjertsen

Leukemia 2012 26: 910-917; advance online publication, November 8, 2011; 10.1038/leu.2011.315

The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis–relapse samples of precursor B-cell acute lymphoblastic leukemia

C E de Bock, A Ardjmand, T J Molloy, S M Bone, D Johnstone, D M Campbell, K L Shipman, T M Yeadon, J Holst, M D Spanevello, G Nelmes, D R Catchpoole, L F Lincz, A W Boyd, G F Burns and R F Thorne

Leukemia 2012 26: 918-926; advance online publication, November 25, 2011; 10.1038/leu.2011.319

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts

G Fuka, H-P Kantner, R Grausenburger, A Inthal, E Bauer, G Krapf, U Kaindl, M Kauer, M N Dworzak, D Stoiber, O A Haas and R Panzer-Grümayer

Leukemia 2012 26: 927-933; advance online publication, November 18, 2011; 10.1038/leu.2011.322

Landscape of TET2 mutations in acute myeloid leukemia

S Weissmann, T Alpermann, V Grossmann, A Kowarsch, N Nadarajah, C Eder, F Dicker, A Fasan, C Haferlach, T Haferlach, W Kern, S Schnittger and A Kohlmann

Leukemia 2012 26: 934-942; advance online publication, November 25, 2011; 10.1038/leu.2011.326

MYELODYSPLASIAS

Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment

M Y Follo, D Russo, C Finelli, S Mongiorgi, C Clissa, C Filì, C Colombi, M Gobbi, L Manzoli, M Piazzi, A M Martelli and L Cocco

Leukemia 2012 26: 943-950; advance online publication, October 28, 2011; 10.1038/leu.2011.300

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis

C Teodosio, A C García-Montero, M Jara-Acevedo, I Álvarez-Twose, L Sánchez-Muñoz, J Almeida, J M Morgado, A Matito, L Escribano and A Orfao

Leukemia 2012 26: 951-958; advance online publication, November 4, 2011; 10.1038/leu.2011.293

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

F J Giles, H M Kantarjian, P D le Coutre, M Baccarani, F-X Mahon, R E Blakesley, N J Gallagher, K Gillis, S L Goldberg, R A Larson, A Hochhaus and O G Ottmann

Leukemia 2012 26: 959-962; advance online publication, December 13, 2011; 10.1038/leu.2011.355

CHRONIC LYMPHOCYTIC LEUKEMIA

Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases

R M Linka, S L Risse, K Bienemann, M Werner, Y Linka, F Krux, C Synaeve, R Deenen, S Ginzel, R Dvorsky, M Gombert, A Halenius, R Hartig, M Helminen, A Fischer, P Stepensky, K Vettenranta, K Köhrer, M R Ahmadian, H-J Laws, B Fleckenstein, H Jumaa, S Latour, B Schraven and A Borkhardt

Leukemia 2012 26: 963-971; advance online publication, January 6, 2012; 10.1038/leu.2011.371

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium

W Wiktor-Jedrzejczak, C Dearden, L de Wreede, A van Biezen, L Brinch, V Leblond, M Brune, L Volin, M Kazmi, A Nagler, J Schetelig, T de Witte and P Dreger on behalf of the EBMT Chronic Leukemia Working Party

Leukemia 2012 26: 972-976; advance online publication, November 25, 2011; 10.1038/leu.2011.304

STEM CELLS

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib

J J W M Janssen, W Deenik, K G M Smolders, B J van Kuijk, W Pouwels, A Kelder, J J Cornelissen, G J Schuurhuis and G J Ossenkoppele

Leukemia 2012 26: 977-984; advance online publication, December 9, 2011; 10.1038/leu.2011.347

MINIMAL RESIDUAL DISEASE

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

E Weisberg, A K Azab, P W Manley, A L Kung, A L Christie, R Bronson, I M Ghobrial and J D Griffin

Leukemia 2012 26: 985-990; advance online publication, December 20, 2011; 10.1038/leu.2011.360

IMMUNOLOGY

Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)

C Buechele, T Baessler, S Wirths, J U Schmohl, B J Schmiedel and H R Salih

Leukemia 2012 26: 991-1000; advance online publication, November 8, 2011; 10.1038/leu.2011.313

SENSITIVITY AND RESISTANCE TO THERAPY

IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase

A B A Laranjeira, J F de Vasconcellos, L Sodek, M C Spago, M C Fornazim, L G Tone, S R Brandalise, A E Nowill and J A Yunes

Leukemia 2012 26: 1001-1011; advance online publication, October 18, 2011; 10.1038/leu.2011.289

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12

M A Mulaw, A J Krause, A J Deshpande, L F Krause, A Rouhi, R La Starza, A Borkhardt, C Buske, C Mecucci, W-D Ludwig, C Lottaz and S K Bohlander

Leukemia 2012 26: 1012-1019; advance online publication, November 8, 2011; 10.1038/leu.2011.307

APOPTOSIS

RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis

S Löder, M Fakler, H Schoeneberger, S Cristofanon, J Leibacher, N Vanlangenakker, M J M Bertrand, P Vandenabeele, I Jeremias, K-M Debatin and S Fulda

Leukemia 2012 26: 1020-1029; advance online publication, December 16, 2011; 10.1038/leu.2011.353

ANIMAL MODELS

Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML

M Schemionek, T Spieker, L Kerstiens, C Elling, M Essers, A Trumpp, W E Berdel, C Müller-Tidow and S Koschmieder

Leukemia 2012 26: 1030-1037; advance online publication, December 23, 2011; 10.1038/leu.2011.366

Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis

T Oki, J Kitaura, N Watanabe-Okochi, K Nishimura, A Maehara, T Uchida, Y Komeno, F Nakahara, Y Harada, T Sonoki, H Harada and T Kitamura

Leukemia 2012 26: 1038-1045; advance online publication, November 25, 2011; 10.1038/leu.2011.328

LYMPHOMA

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma

S M Ansell, H Tang, P J Kurtin, P A Koenig, G S Nowakowski, D A Nikcevich, G D Nelson, Z Yang, D M Grote, S C Ziesmer, P T Silberstein, C Erlichman and T E Witzig

Leukemia 2012 26: 1046-1052; advance online publication, October 21, 2011; 10.1038/leu.2011.297

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells

P Amé-Thomas, J Le Priol, H Yssel, G Caron, C Pangault, R Jean, N Martin, T Marafioti, P Gaulard, T Lamy, T Fest, G Semana and K Tarte

Leukemia 2012 26: 1053-1063; advance online publication, October 21, 2011; 10.1038/leu.2011.301

The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation

E Rao, C Jiang, M Ji, X Huang, J Iqbal, G Lenz, G Wright, L M Staudt, Y Zhao, T W McKeithan, W C Chan and K Fu

Leukemia 2012 26: 1064-1072; advance online publication, November 25, 2011; 10.1038/leu.2011.305

MYELOMA

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC

T Holien, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage and A Sundan

Leukemia 2012 26: 1073-1080; advance online publication, September 23, 2011; 10.1038/leu.2011.263

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells

S Lamorte, S Ferrero, S Aschero, L Monitillo, B Bussolati, P Omedè, M Ladetto and G Camussi

Leukemia 2012 26: 1081-1090; advance online publication, October 25, 2011; 10.1038/leu.2011.290

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

A Mahindra, M E Kalaycio, J Vela-Ojeda, D H Vesole, M-J Zhang, P Li, J R Berenson, J M Bird, A Dispenzieri, J L Gajewski, R P Gale, L Holmberg, S Kumar, R A Kyle, H M Lazarus, S Lonial, J Mikhael, G A Milone, R Munker, R Nath, S Saccaro, L Bik To, D T Vogl, B Wirk and P Hari

Leukemia 2012 26: 1091-1097; advance online publication, November 1, 2011; 10.1038/leu.2011.312

CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients

E Martínez-Viñambres, J A García-Trujillo, E Rodríguez-Martín, L M Villar, J Coll and E Roldán

Leukemia 2012 26: 1098-1105; advance online publication, December 2, 2011; 10.1038/leu.2011.335

Letters to the Editor

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

K H Metzeler, A Walker, S Geyer, R Garzon, R B Klisovic, C D Bloomfield, W Blum and G Marcucci

Leukemia 2012 26: 1106-1107; advance online publication, November 29, 2011; 10.1038/leu.2011.342

Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34

K Shedden, Y Li, P Ouillette and S N Malek

Leukemia 2012 26: 1108-1110; advance online publication, December 20, 2011; 10.1038/leu.2011.361

NPM-MLF1 synergizes with Npm haploinsufficiency to enhance myeloid progenitor activity

W-H Lee, S Salek-Ardakani, P P Pandolfi, H J M Brady, J de Boer and O Williams

Leukemia 2012 26: 1110-1112; advance online publication, December 23, 2011; 10.1038/leu.2011.365

Stromal cells and CD40 ligand (CD154) alter the miRNome and induce miRNA clusters including, miR-125b/miR-99a/let-7c and miR-17-92 in chronic lymphocytic leukaemia

S Willimott and S D Wagner

Leukemia 2012 26: 1113-1116; advance online publication, October 25, 2011; 10.1038/leu.2011.299

β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway

K Sukhdeo, M Mani, T Hideshima, K Takada, V Pena-Cruz, G Mendez, S Ito, K C Anderson and D R Carrasco

Leukemia 2012 26: 1116-1119; advance online publication, November 4, 2011; 10.1038/leu.2011.303

Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

S Sinha, M A Gertz, M Q Lacy, A Dispenzieri, S R Hayman, F K Buadi, D Dingli, I N Micallef, W J Hogan, D A Gastineau, S V Rajkumar and S K Kumar

Leukemia 2012 26: 1119-1122; advance online publication, October 28, 2011; 10.1038/leu.2011.308

Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice

C R Moore, Y Liu, C Shao, L R Covey, H C Morse, III and P Xie

Leukemia 2012 26: 1122-1127; advance online publication, October 28, 2011; 10.1038/leu.2011.309

Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

E Kostareli, M Gounari, A Janus, F Murray, X Brochet, V Giudicelli, S Pospisilova, D Oscier, L Foroni, P F di Celle, B Tichy, L B Pedersen, J Jurlander, M Ponzoni, A Kouvatsi, A Anagnostopoulos, K Thompson, N Darzentas, M-P Lefranc, C Belessi, R Rosenquist, F Davi, P Ghia and K Stamatopoulos

Leukemia 2012 26: 1127-1131; advance online publication, November 4, 2011; 10.1038/leu.2011.311

AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia

J Dunne, D Mannari, T Farzaneh, A Gessner, F W van Delft, O Heidenreich, B D Young and D M Gascoyne

Leukemia 2012 26: 1131-1135; advance online publication, November 8, 2011; 10.1038/leu.2011.316

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients

T L Lasho, C M Finke, C A Hanson, T Jimma, R A Knudson, R P Ketterling, A Pardanani and A Tefferi

Leukemia 2012 26: 1135-1137; advance online publication, November 8, 2011; 10.1038/leu.2011.320

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

F Damm, F Thol, O Kosmider, S Kade, P Löffeld, F Dreyfus, A Stamatoullas-Bastard, A Tanguy-Schmidt, O Beyne-Rauzy, S de Botton, A Guerci-Bresler, G Göhring, B Schlegelberger, A Ganser, O A Bernard, M Fontenay and M Heuser

Leukemia 2012 26: 1137-1140; advance online publication, November 8, 2011; 10.1038/leu.2011.321

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

E Traer, R MacKenzie, J Snead, A Agarwal, A M Eiring, T O'Hare, B J Druker and M W Deininger

Leukemia 2012 26: 1140-1143; advance online publication, November 18, 2011; 10.1038/leu.2011.325

Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia

D E Spaner

Leukemia 2012 26: 1144-1145; advance online publication, November 8, 2011; 10.1038/leu.2011.329

Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis

O Meynet, M Bénéteau, M A Jacquin, L A Pradelli, A Cornille, M Carles and J-E Ricci

Leukemia 2012 26: 1145-1147; advance online publication, November 11, 2011; 10.1038/leu.2011.327

Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

G Barosi, A Tefferi and T Barbui on behalf of the ad hoc committee ‘Definition of clinically relevant outcomes for contemporarily clinical trials in Ph-neg MPNs’

Leukemia 2012 26: 1148-1149; advance online publication, November 22, 2011; 10.1038/leu.2011.337

Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells

J Tanaka, J Sugita, S Shiratori, A Shigematu, S Asanuma, K Fujimoto, M Nishio, T Kondo and M Imamura

Leukemia 2012 26: 1149-1152; advance online publication, December 6, 2011; 10.1038/leu.2011.345

Corrigendum

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

S K Kumar, J H Lee, J J Lahuerta, G Morgan, P G Richardson, J Crowley, J Haessler, J Feather, A Hoering, P Moreau, X LeLeu, C Hulin, S K Klein, P Sonneveld, D Siegel, J Bladeé, H Goldschmidt, S Jagannath, J S Miguel, R Orlowski, A Palumbo, O Sezer and S V Rajkumar BGM Durie on behalf of the International Myeloma Working Group

Leukemia 2012 26: 1153; 10.1038/leu.2012.15

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC

T Holien, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage and A Sundan

Leukemia 2012 26: 1154; 10.1038/leu.2012.64